TITLE

Randomized clinical trials: What gets published, and when?

AUTHOR(S)
Hirsch, Laurence
PUB. DATE
February 2004
SOURCE
CMAJ: Canadian Medical Association Journal;2/17/2004, Vol. 170 Issue 4, p481
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Focuses on the associations between the funding of clinical trials by for-profit organizations and the reporting of positive results or conclusions. Difference in the approaches used by pharmaceutical companies in clinical trials and their publication; Need to conduct placebo-controlled trials as a requirement for regulatory approval; Publication bias of the file-drawer phenomenon, in which trials with negative or inconclusive results are not submitted for publication.
ACCESSION #
12157952

 

Related Articles

  • Trial indicates Avanir drug is effective against pseudobulbar affect.  // PharmaWatch: CNS;October 2004, Vol. 3 Issue 10, p5 

    The article presents information about trial of Avanir Pharmaceuticals Inc.'s drug is effective against pseudobulbar affect. Positive results have been reported in a clinical trial of a new treatment for pseudobulbar affect in patients with multiple sclerosis. The Avanir Pharmaceuticals drug,...

  • Placebo effects: clinical aspects and neurobiology.  // Brain: A Journal of Neurology;Nov2008, Vol. 131 Issue 11, p2812 

    Placebo effects are beneficial health outcomes not related to the relatively direct biological effects of an intervention and can be elicited by an agent that, by itself, is inert. Understanding these placebo effects will help to improve clinical trial design, especially for interventions such...

  • Placebo Response in Children's Medication Trials. J. O. // School Health Alert;May2012, Vol. 27 Issue 9, p3 

    The article presents information on a report according to which placebos can impact the determination of actual benefits of products during clinical trials as they garner higher than expected response in children and teenagers.

  • Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review. Meads C; Hyde C // British Journal of Ophthalmology;Feb2004, Vol. 88 Issue 2, p212 

    BACKGROUND: In 2001 the National Institute for Clinical Excellence (NICE) was asked to issue guidance for England and Wales on the use of photodynamic therapy (PDT). This process has been protracted, partly because of a dispute over the magnitude of beneficial effect. This article examines the...

  • LEGAL AND ETHICAL OBLIGATIONS TO CONDUCT A CLINICAL DRUG TRIAL IN AUSTRALIA AS AN INVESTIGATOR INITIATED AND SPONSORED STUDY FOR AN OVERSEAS PHARMACEUTICAL COMPANY. Beran, Roy G. // Medicine & Law (World Association for Medical Law);2004, Vol. 23 Issue 4, p913 

    Most multi-centre trials are both financed and sponsored by the pharmaceutical company involved. What follows will map the path adopted for an investigator initiated and sponsored study for a new indication of an established medication. The chief investigators of a company-sponsored,...

  • The Emperor's Sham - wrong assumption that sham needling is sham. Lundeberg, Thomas; Lund, Iréne; Näslund, Jan; Thomas, Moolamanil // Acupuncture in Medicine;Dec2008, Vol. 26 Issue 4, p239 

    During the last five years a large number of randomised controlled clinical trials (RCTs) have been published on the efficacy of acupuncture in different conditions. In most of these studies verum is compared with sham acupuncture. In general both verum and sham have been found to be effective,...

  • Depressing news. Wiedemann, Claudia // Nature Reviews Neuroscience;Apr2008, Vol. 9 Issue 4, p252 

    The article reports on the meta-analysis concerning clinical trials that resulted in the licensing of prescribed antidepressants including the selective serotonin reuptake inhibitors (SSRIs) Prozac, Seroxat, Effexor, and Serzone. It is cited that the effectiveness of these drugs has been...

  • Expert committee to formulate policy and guidelines for approval of new drugs, clinical trials and banning of drugs-comments. Ghooi, Ravindra B. // Perspectives in Clinical Research;Jul-Sep2014, Vol. 5 Issue 3, p100 

    All is not well with the clinical research industry. Instances of scientific misconduct by investigators, cutting corners by sponsors, irregularities by regulators, have brought a bad name to the industry. These however form a small part of the clinical research done in this country. The US FDA...

  • Beyond PubMed: Searching the “Grey Literature” for Clinical Trial Results. Citrome, Leslie // Innovations in Clinical Neuroscience;Jul/Aug2014, Vol. 11 Issue 7/8, p42 

    Clinical trial results have been traditionally communicated through the publication of scholarly reports and reviews in biomedical journals. However, this dissemination of information can be delayed or incomplete, making it difficult to appraise new treatments, or in the case of missing data,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics